{"title":"[Body weight and bone/calcium metabolism. The effect of incretin hormones on bone and calcium metabolism.]","authors":"Yuka Kinoshita","doi":"CliCa1807933939","DOIUrl":null,"url":null,"abstract":"<p><p>Incretins are gastro-intestinal hormones released from enteroendocrine cells in response to food intake. Incretins such as glucose-dependent insulinotropic peptide(GIP)and glucagon-like peptide 1(GLP-1)modulate glucose homeostasis by regulating glucose-dependent insulin release from pancreatic βcells. Dipeptidyl peptidase-4(DPP-4)inhibitors and GLP-1 receptor agonists are incretin-based drugs that have been used for the management of hyperglycemia and obesity in patients with type 2 diabetes mellitus. Although experimental studies have shown that incretin improves bone quality and increases bone mass in rodents, further studies are necessary to clarify the effect of incretin-based drugs on bone mineral density and risk of fractures in humans.</p>","PeriodicalId":10389,"journal":{"name":"Clinical calcium","volume":"28 7","pages":"933-939"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical calcium","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/CliCa1807933939","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Incretins are gastro-intestinal hormones released from enteroendocrine cells in response to food intake. Incretins such as glucose-dependent insulinotropic peptide(GIP)and glucagon-like peptide 1(GLP-1)modulate glucose homeostasis by regulating glucose-dependent insulin release from pancreatic βcells. Dipeptidyl peptidase-4(DPP-4)inhibitors and GLP-1 receptor agonists are incretin-based drugs that have been used for the management of hyperglycemia and obesity in patients with type 2 diabetes mellitus. Although experimental studies have shown that incretin improves bone quality and increases bone mass in rodents, further studies are necessary to clarify the effect of incretin-based drugs on bone mineral density and risk of fractures in humans.